aztreonam has been researched along with Pneumonia in 30 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia." | 9.09 | Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. ( Cammarata, S; Oliphant, T; Rubinstein, E; Wunderink, R, 2001) |
| "The combination aztreonam + cefotaxime (AZ + CE) was compared to amikacin + cefotaxime (AM + CE) in the treatment of nosocomial pneumonia acquired at the intensive-care unit." | 9.06 | Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime. ( Agusti Vidal, A; Almela, M; de Celis, R; Deulofeu, R; Marco, F; Rabinad, E; Rodriguez-Roisin, R; Torres, A, 1989) |
| "During the course of one year, 47 critical care patients with gram-negative bacillary pneumonia at Millard Fillmore Hospital were randomly assigned to aztreonam or tobramycin therapy (two to one)." | 9.05 | Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. ( Schentag, JJ; Simons, GW; Smith, IL; Swanson, DJ; Vari, AJ; Vigano, A; Winslade, NE, 1985) |
| "The therapeutic efficacies of the newer beta-lactam antibiotics piperacillin, azlocillin and aztreonam were compared with the efficacies of ticarcillin and tobramycin in a guinea pig model of experimental Pseudomonas aeruginosa pneumonia." | 7.67 | Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. ( Pennington, JE; Schiff, JB, 1984) |
| "Nineteen patients with community- or hospital-acquired gram-negative pneumonia were treated with aztreonam." | 7.67 | Aztreonam therapy for gram-negative pneumonia. ( Bollinger, M; Greenberg, RN; Luppen, KL; McMillian, R; Reilly, PM, 1985) |
| "Gram-negative pneumonia is a frequent complication in hospitalized patients, particularly in those with diminished defenses." | 6.66 | Comparative study of aztreonam in gram-negative pneumonia versus a therapeutic regimen that includes an aminoglycoside. Spanish Study Group. ( Gobernado, M; Marco, V; Rabinad, E; Santos, M, 1989) |
| "Aztreonam is a synthetic, monobactam antibiotic structurally related to the beta-lactam class of drugs." | 5.28 | Aztreonam-induced myelosuppression during treatment of Pseudomonas aeruginosa pneumonia. ( Czachor, JS; Dallal, MM, 1991) |
| "Aztreonam was then discontinued and the patient was treated with supportive measures and steroids and his renal failure reversed over the course of 5 days." | 5.27 | Acute renal failure, skin rash, and eosinophilia associated with aztreonam. ( Pazmiño, P, 1988) |
| " This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia." | 5.09 | Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. ( Cammarata, S; Oliphant, T; Rubinstein, E; Wunderink, R, 2001) |
| "The combination aztreonam + cefotaxime (AZ + CE) was compared to amikacin + cefotaxime (AM + CE) in the treatment of nosocomial pneumonia acquired at the intensive-care unit." | 5.06 | Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime. ( Agusti Vidal, A; Almela, M; de Celis, R; Deulofeu, R; Marco, F; Rabinad, E; Rodriguez-Roisin, R; Torres, A, 1989) |
| "During the course of one year, 47 critical care patients with gram-negative bacillary pneumonia at Millard Fillmore Hospital were randomly assigned to aztreonam or tobramycin therapy (two to one)." | 5.05 | Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. ( Schentag, JJ; Simons, GW; Smith, IL; Swanson, DJ; Vari, AJ; Vigano, A; Winslade, NE, 1985) |
| "The therapeutic efficacies of the newer beta-lactam antibiotics piperacillin, azlocillin and aztreonam were compared with the efficacies of ticarcillin and tobramycin in a guinea pig model of experimental Pseudomonas aeruginosa pneumonia." | 3.67 | Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. ( Pennington, JE; Schiff, JB, 1984) |
| "Aztreonam was administered to 20 children diagnosed as having any of the following infections: urinary tract infection, pneumonia, meningitis, and abscess of the appendix." | 3.67 | Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients. ( Arango, A; Benítez, G; Castrillón, AL; Harry, N; Mejía, GI; Restrepo, F; Trujillo, H, 1989) |
| "The pharmacokinetics of aztreonam were studied in ten critically ill intubated patients with lower respiratory tract infections." | 3.67 | The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients. ( Boccazzi, A; Langer, M; Mandelli, M; Ranzi, AM; Urso, R, 1989) |
| "Nineteen patients with community- or hospital-acquired gram-negative pneumonia were treated with aztreonam." | 3.67 | Aztreonam therapy for gram-negative pneumonia. ( Bollinger, M; Greenberg, RN; Luppen, KL; McMillian, R; Reilly, PM, 1985) |
| " An adequate standard dosage of aztreonam could be established as 3-4 g/day in compromised patients, and it should be combined with gram-positive coverage when used empirically." | 2.66 | A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients. ( Bosch-Perez, A; Rabinad, E, 1989) |
| "Gram-negative pneumonia is a frequent complication in hospitalized patients, particularly in those with diminished defenses." | 2.66 | Comparative study of aztreonam in gram-negative pneumonia versus a therapeutic regimen that includes an aminoglycoside. Spanish Study Group. ( Gobernado, M; Marco, V; Rabinad, E; Santos, M, 1989) |
| "Patients with a beta-lactam allergy label (BLAL) were found to have decreased utilization of beta-lactams (p < ." | 1.72 | Effects of reported beta-lactam allergies on pneumonia outcomes in lung transplant recipients. ( Axelrod, P; Holaday, E; Mishkin, A; Motzer, AR, 2022) |
| "While group C beta hemolytic streptococcal infections are uncommon in humans, group C beta hemolytic streptococcal pneumonia is exceedingly rare." | 1.38 | Necrotizing pneumonia caused by group C streptococci in a young adult. ( Hurtado Rendon, IS; Pathak, V; Smina, M, 2012) |
| "Aztreonam is a synthetic, monobactam antibiotic structurally related to the beta-lactam class of drugs." | 1.28 | Aztreonam-induced myelosuppression during treatment of Pseudomonas aeruginosa pneumonia. ( Czachor, JS; Dallal, MM, 1991) |
| "Aztreonam was used for a year to treat 106 hospitalized patients with a total of 131 documented gram-negative infections." | 1.27 | Treatment of serious gram-negative infections with aztreonam. ( Bollinger, M; Darji, TB; Greenberg, RN; Luppen, KL; McMillian, R; Noorani, AA; Reilly, PM; Wolk, SM, 1984) |
| "Aztreonam was then discontinued and the patient was treated with supportive measures and steroids and his renal failure reversed over the course of 5 days." | 1.27 | Acute renal failure, skin rash, and eosinophilia associated with aztreonam. ( Pazmiño, P, 1988) |
| "Aztreonam is a novel antimicrobial agent belonging to the monobactam class of antibiotics." | 1.27 | Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. ( Neu, HC; Scully, BE, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (53.33) | 18.7374 |
| 1990's | 7 (23.33) | 18.2507 |
| 2000's | 2 (6.67) | 29.6817 |
| 2010's | 3 (10.00) | 24.3611 |
| 2020's | 2 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bitew, A | 1 |
| Bati, S | 1 |
| Bigaud, M | 1 |
| Rudolph, B | 1 |
| Briard, E | 1 |
| Beerli, C | 1 |
| Hofmann, A | 1 |
| Hermes, E | 1 |
| Muellershausen, F | 1 |
| Schubart, A | 1 |
| Gardin, A | 1 |
| Hed, S | 1 |
| Matlov Kormas, R | 1 |
| Shashar, S | 1 |
| Malyugin, BE | 1 |
| Boyko, M | 1 |
| Knyazer, B | 1 |
| Nguyen Truong, G | 1 |
| Hoang Vinh, L | 1 |
| Huynh Thu, S | 1 |
| Nguyen Thi Hong, P | 1 |
| Nguyen Quang, B | 1 |
| White, MG | 1 |
| Szczepaniak Sloane, R | 1 |
| Witt, RG | 1 |
| Reuben, A | 1 |
| Gaudreau, PO | 1 |
| Andrews, MC | 1 |
| Feng, N | 1 |
| Johnson, S | 1 |
| Class, CA | 1 |
| Bristow, C | 1 |
| Wani, K | 1 |
| Hudgens, C | 1 |
| Nezi, L | 1 |
| Manzo, T | 1 |
| De Macedo, MP | 1 |
| Hu, J | 2 |
| Davis, R | 1 |
| Jiang, H | 1 |
| Prieto, P | 1 |
| Burton, E | 1 |
| Hwu, P | 1 |
| Tawbi, H | 1 |
| Gershenwald, J | 1 |
| Lazar, AJ | 1 |
| Tetzlaff, MT | 1 |
| Overwijk, W | 1 |
| Woodman, SE | 1 |
| Cooper, ZA | 1 |
| Marszalek, JR | 1 |
| Davies, MA | 1 |
| Heffernan, TP | 1 |
| Wargo, JA | 1 |
| Jha, V | 1 |
| Purohit, H | 1 |
| Dafale, NA | 1 |
| Moursi, AS | 1 |
| El-Fishawy, N | 1 |
| Djahel, S | 1 |
| Shouman, MA | 1 |
| Li, C | 1 |
| Yu, L | 1 |
| Jiang, Y | 1 |
| Cui, Y | 1 |
| Liu, Y | 1 |
| Shi, K | 1 |
| Hou, H | 1 |
| Liu, M | 1 |
| Zhang, W | 2 |
| Zhang, J | 1 |
| Zhang, C | 1 |
| Chen, M | 3 |
| Lu, L | 1 |
| Zheng, P | 1 |
| Wu, Z | 1 |
| Chen, X | 1 |
| Parisi, A | 1 |
| Cortellini, A | 1 |
| Venditti, O | 1 |
| Filippi, R | 1 |
| Salvatore, L | 1 |
| Tortora, G | 1 |
| Ghidini, M | 1 |
| Nigro, O | 1 |
| Gelsomino, F | 1 |
| Zurlo, IV | 1 |
| Fulgenzi, C | 1 |
| Lombardi, P | 1 |
| Roselló Keränen, S | 1 |
| Depetris, I | 1 |
| Giampieri, R | 1 |
| Morelli, C | 1 |
| Di Marino, P | 1 |
| Di Pietro, FR | 1 |
| Zanaletti, N | 1 |
| Vitale, P | 1 |
| Garajova, I | 1 |
| Spinelli, GP | 1 |
| Zoratto, F | 1 |
| Roberto, M | 1 |
| Petrillo, A | 1 |
| Aimar, G | 1 |
| Patruno, L | 1 |
| D'Orazio, C | 1 |
| Ficorella, C | 1 |
| Ferri, C | 1 |
| Porzio, G | 1 |
| Carinato, H | 1 |
| Burgy, M | 1 |
| Ferry, R | 1 |
| Fischbach, C | 1 |
| Kalish, M | 1 |
| Guihard, S | 1 |
| Brahimi, Y | 1 |
| Flesch, H | 1 |
| Bronner, G | 1 |
| Schultz, P | 1 |
| Frasie, V | 1 |
| Thiéry, A | 1 |
| Demarchi, M | 1 |
| Petit, T | 1 |
| Jung, AC | 1 |
| Wagner, P | 1 |
| Coliat, P | 1 |
| Borel, C | 1 |
| Yang, Y | 2 |
| Tang, Z | 1 |
| Ji, J | 1 |
| Yang, C | 1 |
| Han, B | 1 |
| Wang, Y | 2 |
| Guo, H | 1 |
| Gao, X | 1 |
| Wang, J | 1 |
| Cao, J | 1 |
| Zhang, B | 1 |
| Topatana, W | 1 |
| Li, S | 2 |
| Juengpanich, S | 1 |
| Lu, Z | 1 |
| Cai, X | 1 |
| Guan, W | 1 |
| Yang, S | 1 |
| Zhao, Y | 1 |
| Cheng, W | 1 |
| Song, X | 1 |
| Yao, Y | 1 |
| Xie, Y | 1 |
| Du, W | 1 |
| Li, J | 1 |
| Chen, XF | 1 |
| Fan, X | 1 |
| Hou, X | 1 |
| Liu, XY | 1 |
| Huang, JJ | 1 |
| Kang, W | 1 |
| Zhang, G | 1 |
| Zhang, H | 2 |
| Yang, WH | 1 |
| Li, YX | 1 |
| Wang, JW | 1 |
| Guo, DW | 1 |
| Sun, ZY | 1 |
| Chen, ZJ | 1 |
| Zou, LG | 1 |
| Du, XF | 1 |
| Pan, YH | 1 |
| Li, B | 1 |
| He, H | 1 |
| Xu, YC | 1 |
| Shi, D | 1 |
| Anwar, TM | 1 |
| Pan, H | 1 |
| Chai, W | 1 |
| Xu, S | 1 |
| Yue, M | 1 |
| Wang, W | 1 |
| Huang, S | 1 |
| Zou, C | 1 |
| Ding, Y | 1 |
| Wang, H | 2 |
| Pu, S | 1 |
| Liao, Y | 1 |
| Du, H | 1 |
| Wang, D | 1 |
| Chen, L | 1 |
| Niu, S | 1 |
| Harrison, MA | 1 |
| Kaur, H | 1 |
| Wren, BW | 1 |
| Dawson, LF | 1 |
| Yu, Y | 1 |
| Hu, B | 1 |
| Fan, H | 1 |
| Lian, S | 1 |
| Li, H | 1 |
| Yan, X | 1 |
| Wang, S | 1 |
| Bai, X | 1 |
| Mao, F | 1 |
| Chen, Y | 1 |
| Zhang, Q | 1 |
| Ding, X | 1 |
| Ni, B | 1 |
| Xu, X | 1 |
| Jin, X | 1 |
| Dai, Y | 1 |
| Fachler, T | 1 |
| Shteyer, E | 1 |
| Orlanski Meyer, E | 1 |
| Shemasna, I | 1 |
| Lev Tzion, R | 1 |
| Rachman, Y | 1 |
| Bergwerk, A | 1 |
| Turner, D | 1 |
| Ledder, O | 1 |
| Marianeschi, SM | 1 |
| Uricchio, N | 1 |
| Cerri, GB | 1 |
| Ghiselli, S | 1 |
| Carro, C | 1 |
| Albano, G | 1 |
| Viola, N | 1 |
| Li, Y | 1 |
| Zhang, Y | 1 |
| Liu, C | 1 |
| Li, X | 1 |
| Zhou, Q | 1 |
| Sun, C | 2 |
| Zhang, L | 2 |
| Singh, D | 1 |
| Raghunathan, V | 1 |
| Dhaliwal, M | 1 |
| Rastogi, N | 1 |
| Chadha, R | 1 |
| Yadav, SP | 1 |
| Shah, M | 1 |
| Han, JH | 1 |
| Park, H | 1 |
| Kim, HW | 1 |
| Park, KB | 1 |
| Zhou, J | 1 |
| Huang, H | 1 |
| Zhu, Q | 1 |
| Wen, F | 1 |
| Dong, Y | 1 |
| Hu, Y | 1 |
| Pan, P | 1 |
| Hong, C | 1 |
| Fang, L | 1 |
| Motzer, AR | 1 |
| Holaday, E | 1 |
| Axelrod, P | 1 |
| Mishkin, A | 1 |
| Davido, B | 1 |
| Fellous, L | 1 |
| Lawrence, C | 1 |
| Maxime, V | 1 |
| Rottman, M | 1 |
| Dinh, A | 1 |
| Pathak, V | 1 |
| Hurtado Rendon, IS | 1 |
| Smina, M | 1 |
| Giuliano, C | 1 |
| Kale-Pradhan, PB | 1 |
| Johnson, LB | 1 |
| Schiff, JB | 1 |
| Pennington, JE | 1 |
| Greenberg, RN | 2 |
| Reilly, PM | 2 |
| Luppen, KL | 2 |
| McMillian, R | 2 |
| Bollinger, M | 2 |
| Wolk, SM | 1 |
| Darji, TB | 1 |
| Noorani, AA | 1 |
| Toyama, K | 1 |
| Yaguchi, M | 1 |
| Mizoguchi, H | 1 |
| Masuda, M | 1 |
| Urabe, A | 1 |
| Ikeda, Y | 1 |
| Aoki, I | 1 |
| Shinbo, T | 1 |
| Togawa, A | 1 |
| Hirashima, K | 1 |
| Miura, Y | 1 |
| Hirose, S | 1 |
| Tsuruoka, N | 1 |
| Omine, M | 1 |
| Kamakura, M | 1 |
| Saito, T | 1 |
| Arimori, S | 1 |
| Aoki, N | 1 |
| Kuraishi, Y | 1 |
| Hirai, H | 1 |
| Asano, S | 1 |
| Mori, M | 1 |
| Shirai, T | 1 |
| Muto, Y | 1 |
| Takaku, F | 1 |
| Polk, HC | 1 |
| Livingston, DH | 1 |
| Fry, DE | 1 |
| Malangoni, MA | 1 |
| Fabian, T | 1 |
| Trachtenberg, LS | 1 |
| Gardner, SA | 1 |
| Kesterson, L | 1 |
| Cheadle, WG | 1 |
| Boucher, BA | 1 |
| Rubinstein, E | 1 |
| Cammarata, S | 1 |
| Oliphant, T | 1 |
| Wunderink, R | 1 |
| Goto, J | 1 |
| Sakata, Y | 1 |
| Sawada, Y | 1 |
| Kuroe, K | 1 |
| Nakaji, S | 1 |
| Takami, H | 1 |
| Tsushima, K | 1 |
| Saito, S | 1 |
| Ogasawara, H | 1 |
| Shinagawa, H | 1 |
| Soma, N | 1 |
| Fayed, DF | 1 |
| Dahmash, NS | 1 |
| Saddique, AA | 1 |
| Shibl, AM | 1 |
| Dallal, MM | 1 |
| Czachor, JS | 1 |
| Cook, JL | 2 |
| Rabinad, E | 3 |
| Bosch-Perez, A | 1 |
| Torres, A | 1 |
| de Celis, R | 1 |
| Marco, F | 1 |
| Almela, M | 1 |
| Deulofeu, R | 1 |
| Rodriguez-Roisin, R | 1 |
| Agusti Vidal, A | 1 |
| Rivera-Vazquez, CR | 1 |
| Ramirez-Ronda, CH | 1 |
| Rodriguez, JR | 1 |
| Saavedra, S | 1 |
| Marco, V | 1 |
| Gobernado, M | 1 |
| Santos, M | 1 |
| Trujillo, H | 1 |
| Harry, N | 1 |
| Arango, A | 1 |
| Benítez, G | 1 |
| Restrepo, F | 1 |
| Mejía, GI | 1 |
| Castrillón, AL | 1 |
| Boccazzi, A | 1 |
| Langer, M | 1 |
| Mandelli, M | 1 |
| Ranzi, AM | 1 |
| Urso, R | 1 |
| Pazmiño, P | 1 |
| Roselle, GA | 1 |
| Sklavunu-Tsurutsoglu, S | 1 |
| Gatzola-Karaveli, M | 1 |
| Hitoglu-Makedu, A | 1 |
| Paradelis, AG | 1 |
| Tsurutsoglu, G | 1 |
| Schentag, JJ | 1 |
| Vari, AJ | 1 |
| Winslade, NE | 1 |
| Swanson, DJ | 1 |
| Smith, IL | 1 |
| Simons, GW | 1 |
| Vigano, A | 1 |
| Saito, A | 2 |
| Shiba, K | 1 |
| Miyahara, T | 1 |
| Ueda, Y | 1 |
| Terai, T | 1 |
| Abe, S | 1 |
| Yamaguchi, E | 1 |
| Okazaki, N | 1 |
| Kawakami, Y | 1 |
| Scully, BE | 1 |
| Neu, HC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Vitro and in Ventilator-associated Pneumonia[NCT01356472] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for aztreonam and Pneumonia
| Article | Year |
|---|---|
Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient.
Topics: Aztreonam; Cost-Benefit Analysis; Critical Illness; Cross Infection; Drug Costs; Humans; Monobactams | 2000 |
Role of aztreonam in lower respiratory tract infections.
Topics: Aztreonam; Bacterial Infections; Cross Infection; Drug Evaluation; Gram-Negative Bacteria; Humans; I | 1988 |
10 trials available for aztreonam and Pneumonia
| Article | Year |
|---|---|
Effect of recombinant human granulocyte colony-stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Clindamycin; Drug Therapy, Com | 1996 |
Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial.
Topics: Aztreonam; Bronchoalveolar Lavage Fluid; Cilastatin; Cross Infection; Drug Therapy, Combination; HLA | 1997 |
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Cross Infection; Doubl | 2001 |
[A randomized controlled study on imipenem/cilastatin sodium in comparison to aztreonam + lincomycin in treating severe infections in patients with malignant tumors or hematological diseases].
Topics: Adolescent; Adult; Aged; Aztreonam; Cilastatin; Drug Therapy, Combination; Female; Hematologic Disea | 1992 |
Evaluation of aztreonam in the treatment of serious gram-negative infections in a university hospital in Saudi Arabia.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aztreonam; Bacteremia; Citrobacter; Cross Infection; | 1992 |
A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacterial Infecti | 1989 |
Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime.
Topics: Adult; Aged; Amikacin; Aztreonam; Cefotaxime; Clinical Trials as Topic; Cross Infection; Drug Therap | 1989 |
A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Aztreonam; Bacterial Infections; Clindamycin; Clinical Tri | 1989 |
Comparative study of aztreonam in gram-negative pneumonia versus a therapeutic regimen that includes an aminoglycoside. Spanish Study Group.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacterial Infecti | 1989 |
Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Clinical Trials as Topic; Critical Car | 1985 |
18 other studies available for aztreonam and Pneumonia
| Article | Year |
|---|---|
Topics: Animals; Anti-Bacterial Agents; Antibodies, Protozoan; Antifungal Agents; Auranofin; Azabicyclo Comp | 2021 |
Effects of reported beta-lactam allergies on pneumonia outcomes in lung transplant recipients.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Clostridium Infect | 2022 |
Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacteremia; beta-Lactam Resistance; be | 2017 |
Necrotizing pneumonia caused by group C streptococci in a young adult.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Clindamycin; Drug Therapy, Combination; Humans; Lung Absces | 2012 |
Early response of ceftaroline fosamic in the treatment of soft-tissue infections.
Topics: Anti-Bacterial Agents; Aztreonam; Ceftaroline; Cephalosporins; Community-Acquired Infections; Endpoi | 2012 |
Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Azlocillin; Aztreonam; Guinea Pigs; Penicillins; Piperacillin; Pneum | 1984 |
Treatment of serious gram-negative infections with aztreonam.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Drug Evaluation; En | 1984 |
Aerobic and anaerobic bacterial interactions in the development of anaerobic bacterial pneumonia.
Topics: Animals; Aztreonam; Bacteroides fragilis; Clindamycin; Escherichia coli; Female; Guinea Pigs; Inject | 1992 |
Aztreonam-induced myelosuppression during treatment of Pseudomonas aeruginosa pneumonia.
Topics: Aztreonam; Bone Marrow; Bone Marrow Diseases; Humans; Male; Middle Aged; Pneumonia; Pseudomonas Infe | 1991 |
Gram-negative bacillary pneumonia in the nosocomial setting. Role of aztreonam therapy.
Topics: Aztreonam; Bacterial Infections; Cross Infection; Gram-Negative Bacteria; Humans; Microbial Sensitiv | 1990 |
Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients.
Topics: Abscess; Aerobiosis; Appendix; Aztreonam; Bacterial Infections; Cecal Diseases; Child, Preschool; Fe | 1989 |
The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients.
Topics: Adolescent; Adult; Aged; Aztreonam; Bronchi; Critical Care; Female; Gram-Negative Bacteria; Humans; | 1989 |
Acute renal failure, skin rash, and eosinophilia associated with aztreonam.
Topics: Acute Kidney Injury; Aged; Aztreonam; Combined Modality Therapy; Drug Eruptions; Eosinophilia; Human | 1988 |
Nosocomial and nursing home-acquired pneumonia. Recent therapeutic advances.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Cilastatin; Clavulanic Acid; Clavulanic Acids; Cro | 1987 |
Aztreonam in gram-negative infections in children.
Topics: Aztreonam; Bacterial Infections; Child; Child, Preschool; Female; Gram-Negative Bacteria; Humans; In | 1987 |
Aztreonam therapy for gram-negative pneumonia.
Topics: Adult; Aged; Alcoholism; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Cross Infection; Dr | 1985 |
[A comparative study between aztreonam and cefoperazone in respiratory tract infections].
Topics: Adolescent; Adult; Aged; Aztreonam; Cefoperazone; Female; Haemophilus influenzae; Humans; Male; Midd | 1985 |
Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infectio | 1985 |